SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-004262
Filing Date
2019-05-07
Accepted
2019-05-07 16:16:07
Documents
57
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q btai-20190331x10q.htm 10-Q 1456921
2 EX-31.1 btai-20190331ex3116dbbd0.htm EX-31.1 20824
3 EX-31.2 btai-20190331ex312b6301f.htm EX-31.2 20560
4 EX-32.1 btai-20190331ex321c34036.htm EX-32.1 10731
5 EX-32.2 btai-20190331ex32292614f.htm EX-32.2 9548
  Complete submission text file 0001558370-19-004262.txt   4162835

Data Files

Seq Description Document Type Size
6 EX-101.INS btai-20190331.xml EX-101.INS 588460
7 EX-101.SCH btai-20190331.xsd EX-101.SCH 35438
8 EX-101.CAL btai-20190331_cal.xml EX-101.CAL 33710
9 EX-101.DEF btai-20190331_def.xml EX-101.DEF 100665
10 EX-101.LAB btai-20190331_lab.xml EX-101.LAB 302742
11 EX-101.PRE btai-20190331_pre.xml EX-101.PRE 230177
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38410 | Film No.: 19803325
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences